^
Association details:
| Biomarker: | CDA underexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Published date:
11/17/2021
Excerpt:
Low CDA transcript was prognostic regardless of arm; 24.8 v 21.2 months with gemcitabine (p = 0.02) and 26.4 v 14.6 months with 5-FU (p = 0.02)....The median survival for patients treated with 5-FU expressing the upper tertile (high) CDA mRNA was 14.6 (95% CI = 8.4–24.1) months compared with 26.4 (95% CI = 21.4–29.7) months for the remaining patients, defined as low CDA expressers (χ2 = 5.18, p = 0.02) (Figure 2A).
DOI:
10.3390/cancers13225758
